In the past few years, a number of new migraine treatments have emerged, including monoclonal antibodies against calcitonin gene-related peptide (CGRP) and the CGRP receptor. Now, a position statement from the American Headache Society offers guidance on the integration of these agents into clinical practice in the prevention of migraine.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Humphrey, P. P. et al. Sumatriptan succinate. Drugs Future 14, 35–39 (1989).
American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 59, 1–18 (2019).
Goadsby, P. J., Edvinsson, L. & Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183–187 (1990).
Edvinsson, L. et al. in The CGRP Family: Calcitonin Gene-Related Peptide (CGRP), Amylin, and Adrenomedullin (eds Poyner, D., Marshall, I. & Brain, S.) 167–171 (Landes Bioscience, 2000).
Zhu, Y. et al. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol. Sci. 39, 2097–2106 (2018).
Edvinsson, L. et al. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat. Rev. Neurol. 14, 338–350 (2018).
Lipton, R. B. et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J. Med. Econ. 21, 666–675 (2018).
H.C.D. has received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from Addex Pharma, Alder, Allergan, Almirall, Amgen, Autonomic Technology, AstraZeneca, Bayer Vital, Berlin Chemie, Böhringer Ingelheim, Bristol-Myers Squibb, Chordate, Coherex, CoLucid, Electrocore, GlaxoSmithKline, Grünenthal, Ipsen, Janssen-Cilag, Labrys Biologicals, Lilly, La Roche, 3M Medica, Medtronic, Menerini, Minster, Merck Sharp & Dohme, Neuroscore, Novartis, Johnson & Johnson, Pierre Fabre, Pfizer, Schaper and Brümmer, Sanofi, St. Jude, Teva and Weber & Weber. Financial support for research projects was provided by Allergan, Almirall, AstraZeneca, Bayer, Electrocore, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme and Pfizer. His headache research is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF) and the European Union. H.C.D. has no ownership interest and does not own stocks of any pharmaceutical company. H.C.D. serves on the editorial boards of Cephalalgia and Lancet Neurology. H.C.D. chairs the Clinical Guidelines Committee of the German Society of Neurology and is a member of the Clinical Trials Committee of the International Headache Society.
About this article
Cite this article
Diener, HC. CGRP antibodies for migraine prevention — new kids on the block. Nat Rev Neurol 15, 129–130 (2019). https://doi.org/10.1038/s41582-019-0139-7
Journal of Medicinal Chemistry (2020)
Pediatric Neurology (2020)
Journal of Molecular Neuroscience (2020)